ArticleAnnals of surgical oncology2026
A Longitudinal Study on Development and Validation of the Prostate Cancer Scale Among the System of Quality of Life Instruments for Patients with Cancer (QLICP-PR V2.0) Based on Classical Test Theory and Generalizability Theory.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe purpose of this study was to develop and validate the prostate cancer scale among the system of quality-of-life instruments for patients with cancer (QLICP-PR V2.0) to provide a reliable tool for assessing quality of life changes and clinical outcomes. PATIENTS AND
methodsApplication of programmed decision procedures, including multiple qualitative and quantitative analyses with general module and specific module combination pattern, were utilized to develop the QLICP-PR V2.0. On the basis of the data from 115 admitted and discharged patients with prostate cancer, the reliability, validity, and responsiveness of the QLICP-PR V2.0 scale were evaluated using correlation analysis, multi-trait scaling analysis, factor analysis, structural equation model, and paired t-tests, as well as combined with generalizability theory.
resultsCronbach's alpha, test-retest reliability, and intra-class correlation coefficient of the total scale were 0.886, 0.896, and 0.889, respectively. Correlation analysis and factor analysis confirmed good construct validity and criterion-related validity. The score differences at all five domains and the total scale before and after the treatment were statistically significant (P < 0.05), with the SRM value ranging from - 1.152 to - 0.408, and the total scale was - 1.152. Generalizability theory results showed that the generalization coefficient of the five domains of the scale range from 0.575 to 0.764, and the reliability index between 0.529 and 0.748.
conclusionsThe QLICP-PR V2.0 has good psychometric properties in reliability, validity, and responsiveness, and can be used to evaluate the quality of life of patients with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.